FDA Releases Draft Guidance on Biosimilarity - - BioPharm International

ADVERTISEMENT

FDA Releases Draft Guidance on Biosimilarity


FDA has released draft guidance on the use of clinical pharmacology studies to determine if a proposed therapeutic biologic product is biosimilar to its reference product.  The guidance pertains to products that require pharmacokinetic and pharmacodynamics data to demonstrate biosimilarity. The guidance addresses clinical pharmacology testing for biosimilar products, developing an appropriate clinical pharmacology database, and designing clinical trials.  

The draft guidance is one in a series by FDA for the implementation of the Biologics Price Competition Act of 2009. FDA intends the guidance to “assist sponsors in designing clinical pharmacology studies that can support an application submitted under section 351(k) of the Public Health Service Act (PHS Act).” According to FDA, the guidance may also be helpful for the development of certain products under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act.

Source: FDA.gov

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines

Click here